改良安卡拉痘苗-巴伐利亚北欧疫苗预防猴痘感染的真实世界效果
该研究在加拿大安大略省采用目标试验仿真设计,纳入9803名有细菌性性传播感染或HIV暴露前预防用药史的成年男性,将接种一剂MVA-BN者与未接种者1:1匹配比较。结果显示,一剂MVA-BN对实验室确诊猴痘感染的估计疫苗有效性为58%(95%CI 31%至75%),提示具有中等保护效果。
要点
- 一剂MVA-BN对实验室确诊猴痘感染的估计有效性为58%(95%CI 31%至75%)。
- 接种组猴痘感染率为0.09/1000人日,未接种组为0.20/1000人日。
- 研究采用目标试验仿真设计,接种者与未接种者按年龄、地区等因素1:1匹配。
核心结论
- 在针对性接种规划与猴痘疫情演变背景下,一剂MVA-BN对预防猴痘感染具有中等有效性。
研究设计与样本
- 目标试验仿真设计,基于加拿大安大略省关联数据库,纳入9803名有梅毒检测史且既往一年实验室确诊细菌性性传播感染,或既往一年配取HIV暴露前预防处方的18岁及以上男性。
- 2022年6月12日至10月27日期间,将15天前接种疫苗者与未接种者按年龄、地理区域、既往HIV诊断、既往三年细菌性性传播感染诊断数及既往一年接种非MVA-BN疫苗情况1:1匹配。
主要发现
- 3204名接种者与3204名未接种对照匹配,研究期间共诊断71例猴痘感染。
- 接种组猴痘感染率为0.09/1000人日(95%CI 0.05至0.13),未接种组为0.20/1000人日(95%CI 0.15至0.27),研究期153天。
- 采用Cox比例风险模型估计风险比,一剂MVA-BN对猴痘感染的估计疫苗有效性为58%(95%CI 31%至75%)。
关键数值与推荐
- 主要结局为皮下接种一剂MVA-BN对实验室确诊猴痘感染的疫苗有效性,计算公式为(1-风险比)×100。
临床怎么用
- 对有细菌性性传播感染史或HIV暴露前预防用药史的成年男性,一剂MVA-BN可提供中等程度的猴痘感染保护,可作为针对性接种规划的参考依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To estimate the real world effectiveness of modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine against mpox infection. DESIGN: Emulation of a target trial. SETTING: Linked databases in Ontario, Canada. PARTICIPANTS: 9803 men aged ≥18 years with a history of being tested for syphilis and a laboratory confirmed bacterial sexually transmitted infection (STI) in the previous year, or who filled a prescription for HIV pre-exposure prophylaxis in the previous year. On each day between 12 June 2022 and 27 October 2022, those who had been vaccinated 15 days previously were matched 1:1 with unvaccinated men by age, geographical region, past HIV diagnosis, number of bacterial STI diagnoses in the previous three years, and receipt of any non-MVA-BN vaccine in the previous year. MAIN OUTCOME MEASURE: The main outcome measure was vaccine effectiveness ((1-hazard ratio)×100) of one dose of subcutaneously administered MVA-BN against laboratory confirmed mpox infection. A Cox proportional hazards model was used to estimate hazard ratios to compare the rate of laboratory confirmed mpox between the two groups. RESULTS: 3204 men who received the vaccine were matched to 3204 unvaccinated controls. A total of 71 mpox infections were diagnosed, with 0.09 per 1000 person days (95% confidence interval (CI) 0.05 to 0.13) in the vaccinated group and 0.20 per 1000 person days (0.15 to 0.27) in the unvaccinated group over the study period of 153 days. Estimated vaccine effectiveness of one dose of MVA-BN against mpox infection was 58% (95% CI 31% to 75%). CONCLUSION: The findings of this study, conducted in the context of a targeted vaccination programme and evolving outbreak of mpox, suggest that one dose of MVA-BN is moderately effective in preventing mpox infection.
引用
- Navarro C, Lau C, Buchan SA, et al. Effectiveness of modified vaccinia Ankara-Bavarian Nordic vaccine against mpox infection: emulation of a target trial. BMJ. 2024. PMID: 39260880. doi:10.1136/bmj-2023-078243
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。